share_log

B of A Securities Downgrades FibroGen to Underperform, Lowers Price Target to $2

B of A Securities Downgrades FibroGen to Underperform, Lowers Price Target to $2

B of A 证券将FibroGen的评级下调至表现不佳,将目标股价下调至2美元
Benzinga ·  2023/08/08 20:49

B of A Securities analyst Jason Gerberry downgrades FibroGen (NASDAQ:FGEN) from Neutral to Underperform and lowers the price target from $4 to $2.

B of A Securities分析师杰森·格伯里将FibroGen(纳斯达克股票代码:FGEN)的评级从中性下调至表现不佳,并将目标股价从4美元下调至2美元。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发